Daiwa Securities Group Inc. has increased its stake in Abbott Laboratories (NYSE: ABT) by 6.9% during the second quarter of 2023. According to HoldingsChannel.com, this institutional investor now holds 277,862 shares of the healthcare company after acquiring an additional 18,043 shares in this period. As of its latest filing with the Securities and Exchange Commission (SEC), Daiwa’s investment in Abbott is valued at approximately $37.8 million.
Several other institutional investors have also adjusted their positions in Abbott Laboratories recently. For example, IMG Wealth Management Inc. raised its stake by an impressive 759.1%, bringing its total holdings to 189 shares valued at $26,000. Elequin Capital LP entered the market with a new stake worth $30,000 in the first quarter. Anfield Capital Management LLC increased its position by 81.3% during the second quarter, owning 232 shares valued at $32,000 after purchasing an additional 104 shares.
Curio Wealth LLC exhibited the most significant growth, expanding its stake by a staggering 15,250.0% to own 307 shares worth $42,000. Finally, Pineridge Advisors LLC increased its holdings by 34.6% during the same quarter, now owning 315 shares valued at $43,000. Institutional investors collectively own approximately 75.18% of Abbott Laboratories’ stock.
Abbott Laboratories’ Financial Performance and Dividend Announcement
On Tuesday, Abbott Laboratories’ stock opened at $121.88. The company’s 50-day simple moving average stands at $128.31, while its 200-day average is at $130.72. Abbott has a market capitalization of $211.93 billion, with a price-to-earnings (P/E) ratio of 15.27 and a beta of 0.71. The stock has fluctuated between a 1-year low of $110.86 and a 1-year high of $141.23.
In addition to its stock performance, Abbott Laboratories has also declared a quarterly dividend of $0.59 per share, which was paid to shareholders on November 17, 2023. Shareholders of record as of October 15, 2023 received this dividend, representing an annualized dividend of $2.36 and a yield of 1.9%. Abbott’s dividend payout ratio currently stands at 29.57%.
Analyst Ratings and Market Outlook
Recent adjustments in analyst ratings reflect a generally positive outlook for Abbott Laboratories. Mizuho raised its price objective for Abbott shares from $135.00 to $140.00, maintaining a “neutral” rating. BTIG Research reiterated a “buy” rating with a price target of $145.00, while Sanford C. Bernstein increased its target from $145.00 to $150.00, issuing an “outperform” rating.
Raymond James Financial also raised its target price for Abbott shares from $141.00 to $146.00, maintaining an “outperform” rating. Finally, Barclays increased its price target from $159.00 to $162.00 and rated the stock as “overweight.”
Overall, analysts have rated Abbott Laboratories with two “Strong Buy” ratings, seventeen “Buy” ratings, and four “Hold” ratings. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $147.00.
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and sale of healthcare products globally. The company operates across four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
With its strong financial performance and growing institutional interest, Abbott Laboratories continues to be a significant player in the healthcare sector, reflecting a robust market position and investor confidence.
